| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥1.06B | +9.1% |
| Gross profit | ¥0.39B | — |
| Operating income | ¥0.17B | — |
| Net income | ¥0.15B | -0.4% |
| Gross margin | 36.7% | Net margin 13.9% |
| Revenue Q/Q | -18.1% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.67B | 63.3% |
| R&D | ¥0.07B | 6.6% |
| SG&A | ¥0.14B | 13.2% |
| Tax & other | ¥0.02B | 1.6% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
安科瑞 ・ 飞利信 ・ 朗玛信息 ・ 利德曼 ・ ST荣科 ・ 百纳千成 ・ 吴通控股 ・ 蓝英装备 ・ 博雅生物 ・ *ST三六五 ・ 利亚德 ・ 三诺生物
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies